IL33 and Hepatic fibrosis: Following targeted suppression of the IL-33/ST-2 signaling pathway in combination with ABZ administration, hepatic fibrosis in liver and therapeutic outcomes were assessed through Masson staining, western blot analysis, and liver index measurements.